share_log

Advaxis (NASDAQ:ADXS) Now Covered by Analysts at StockNews.com

Advaxis (NASDAQ:ADXS) Now Covered by Analysts at StockNews.com

AdvAxis(納斯達克：ADXS)現在由StockNews.com的分析師報道
Defense World ·  2022/09/08 02:11

Equities research analysts at StockNews.com started coverage on shares of Advaxis (NASDAQ:ADXS – Get Rating) in a research note issued to investors on Thursday. The brokerage set a "sell" rating on the stock.

斯托克新聞網的股票研究分析師在週四發佈給投資者的一份研究報告中開始報道Advaxis(納斯達克代碼：ADXS-GET Rating)的股票。該經紀公司對該股設定了“賣出”評級。

Advaxis Stock Performance

Advaxis股票表現

ADXS opened at $3.03 on Thursday. The firm has a market cap of $5.50 million, a P/E ratio of -0.45 and a beta of 2.20. Advaxis has a fifty-two week low of $1.02 and a fifty-two week high of $51.60.

ADXS週四開盤報3.03美元。該公司市值為550萬美元，市盈率為-0.45，貝塔係數為2.20。Advaxis的52周低點為1.02美元，52周高點為51.60美元。

Get
到達
Advaxis
前進軸
alerts:
警報：

About Advaxis

關於Advaxis

(Get Rating)

(獲取評級)

Advaxis, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer.
Advaxis，Inc.是一家臨牀階段的生物技術公司，專注於在美國發現、開發和商業化專有的單核細胞增生性李斯特菌(LM)技術抗原遞送產品。該公司正在開發ADXS-PSA，這是用於治療轉移性前列腺癌的第二階段臨牀試驗；ADXS-503，用於治療非小細胞肺癌；以及ADXS-504，用於治療前列腺癌。

See Also

另請參閲

  • Get a free copy of the StockNews.com research report on Advaxis (ADXS)
  • 3 High Margin Chipmakers Bound to Recover
  • 3 Solar Stocks That Will Benefit From the Biden Tariff Holiday
  • REV Group Has A Deep Moat In The World Of EVs
  • Is G-III Apparel Group, Ltd. A Value Trap?
  • Bank Of America Sees Upside In These 2 European Alcohol Stocks
  • 免費獲取StockNews.com關於Advaxis的研究報告(ADXS)
  • 3家高利潤率芯片製造商勢必復甦
  • 將受益於拜登關税假期的3只太陽能股
  • REV集團在電動汽車世界擁有深厚的護城河
  • G-III服裝集團有限公司是價值陷阱嗎？
  • 美國銀行看好這兩隻歐洲酒類股票

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.

接受Advaxis Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Advaxis和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論